Sometimes, although a mutation is identified, a suitable drug may not be available yet. This is where the numerous ongoing active clinical trials play an important role, offering hope for prolonged survival. There are about 120 to 150 trials ongoing in Singapore alone.
When a patient is diagnosed with a cancer, a biopsy of the tumour is done and sent to the lab for analysis. If the cells don’t have a mutation that can be targeted, regular chemotherapy is the treatment of choice. “If a patient has a mutation, we will suggest targeted therapy if it’s available. If not, we’ll offer the patient a clinical trial. Many of these trials are in their final phases, meaning the safety of the new drugs has already been proven,” said
Dr Ravindran Kanesvaran, Consultant,
Division of Medical Oncology,
National Cancer Centre Singapore (NCCS).
And as long as the tumour continues to shrink, the same targeted treatment can be continued. However, in some cases, after about two to three years, the cancer cells evolve and find alternative mutations with which to drive the cancer. “Potentially, if there are drugs that can treat the new mutation, the patient can continue on for years, just like someone with diabetes or other chronic diseases,” said Dr Ravindran.